Rocket Pharmaceuticals Inc [NASDAQ: RCKT] gained 16.78% or 0.48 points to close at $3.34 with a heavy trading volume of 12339157 shares.
It opened the trading session at $3.27, the shares rose to $3.52 and dropped to $3.11, the range by which the price of stock traded the whole day. The daily chart for RCKT points out that the company has recorded -67.98% loss over the past six months.
If we look at the average trading volume of 4.85M shares, RCKT reached to a volume of 12339157 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Rocket Pharmaceuticals Inc [RCKT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RCKT shares is $9.03 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RCKT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Rocket Pharmaceuticals Inc shares, keeping their opinion on the stock as In-line, with their previous recommendation back on May 30, 2025. The new note on the price target was released on May 28, 2025, representing the official price target for Rocket Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $8, while Leerink Partners analysts kept a Market Perform rating on RCKT stock.
The Price to Book ratio for the last quarter was 0.87, with the Price to Cash per share for the same quarter was set at 2.95.
Trading performance analysis for RCKT stock
Rocket Pharmaceuticals Inc [RCKT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.70. With this latest performance, RCKT shares gained by 15.97% in over the last four-week period, additionally sinking by -67.98% over the last 6 months – not to mention a drop of -73.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RCKT stock in for the last two-week period is set at 53.58, with the RSI for the last a single of trading hit 0.26, and the three-weeks RSI is set at 0.33 for Rocket Pharmaceuticals Inc [RCKT]. The present Moving Average for the last 50 days of trading for this stock 3.89, while it was recorded at 3.00 for the last single week of trading, and 9.71 for the last 200 days.
Rocket Pharmaceuticals Inc (RCKT) Capital Structure & Debt Analysis
According to recent financial data for Rocket Pharmaceuticals Inc. ( RCKT), the Return on Equity (ROE) stands at -60.45%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -53.17%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Rocket Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -59.37%, showcasing its effectiveness in deploying capital for earnings.
Rocket Pharmaceuticals Inc (RCKT) Efficiency & Liquidity Metrics
Based on Rocket Pharmaceuticals Inc’s (RCKT) latest financial statements, the Debt-to-Equity Ratio is 0.06%, indicating its reliance on debt financing relative to shareholder equity.
Rocket Pharmaceuticals Inc (RCKT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Rocket Pharmaceuticals Inc. (RCKT) effectively leverages its workforce, generating an average of -$862976.59 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.19% and a Quick Ratio of 9.19%, indicating strong ability to cover short-term liabilities.
Rocket Pharmaceuticals Inc [RCKT]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RCKT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rocket Pharmaceuticals Inc go to 21.48%.
An analysis of Institutional ownership at Rocket Pharmaceuticals Inc [RCKT]
There are presently around $93.45%, or 96.07% of RCKT stock, in the hands of institutional investors. The top three institutional holders of RCKT stocks are: RTW INVESTMENTS, LP with ownership of 17.69 million shares, which is approximately 18.8677%. WELLINGTON MANAGEMENT GROUP LLP, holding 9.16 million shares of the stock with an approximate value of $$197.12 million in RCKT stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$133.33 million in RCKT stock with ownership which is approximately 6.6057%.
